GSK580299 (Cervarix)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Papillomavirus

Phase 3

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

CompletedNCT01190189

GlaxoSmithKlineInfections, Papillomavirus

Start: 2011-04-01End: 2017-11-23Updated: 2019-06-19

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

CompletedNCT01249365

GlaxoSmithKlineInfections, Papillomavirus

Start: 2011-01-24End: 2017-01-10Updated: 2019-11-13